RSLB.F Stock Overview
A medical technology company, provides software solutions for cancer care in the Americas, Europe, Africa, the Asia-Pacific, and the Middle East. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
RaySearch Laboratories AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 18.00 |
| 52 Week High | SEK 18.00 |
| 52 Week Low | SEK 8.33 |
| Beta | 1.34 |
| 11 Month Change | 15.24% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | 200.00% |
| 5 Year Change | 55.17% |
| Change since IPO | 718.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| RSLB.F | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 2.9% | 2.1% | 2.2% |
| 1Y | n/a | 8.2% | 31.6% |
Return vs Industry: Insufficient data to determine how RSLB.F performed against the US Healthcare Services industry.
Return vs Market: Insufficient data to determine how RSLB.F performed against the US Market.
Price Volatility
| RSLB.F volatility | |
|---|---|
| RSLB.F Average Weekly Movement | n/a |
| Healthcare Services Industry Average Movement | 9.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RSLB.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine RSLB.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 414 | Johan Lof | www.raysearchlabs.com |
RaySearch Laboratories AB (publ), a medical technology company, provides software solutions for cancer care in the Americas, Europe, Africa, the Asia-Pacific, and the Middle East. It develops and markets RayStation, a treatment planning system for radiation therapy; RayCare, an oncology information system that manages clinical activities; RayIntelligence, a cloud-based analytics system for monitoring and enhancement of cancer therapy; and RayCommand, a treatment control system that serves as link between the treatment machine and the treatment planning and oncology information systems. The company offers RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, and electron beam radiation therapy; and µ-RayStation, a software platform for planning and evaluation in small animal irradiation research.
RaySearch Laboratories AB (publ) Fundamentals Summary
| RSLB.F fundamental statistics | |
|---|---|
| Market cap | US$620.88m |
| Earnings (TTM) | US$15.85m |
| Revenue (TTM) | US$105.86m |
39.2x
P/E Ratio5.9x
P/S RatioIs RSLB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RSLB.F income statement (TTM) | |
|---|---|
| Revenue | SEK 1.17b |
| Cost of Revenue | SEK 104.50m |
| Gross Profit | SEK 1.06b |
| Other Expenses | SEK 889.45m |
| Earnings | SEK 175.06m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 21, 2025
| Earnings per share (EPS) | 5.11 |
| Gross Margin | 91.06% |
| Net Profit Margin | 14.97% |
| Debt/Equity Ratio | 0% |
How did RSLB.F perform over the long term?
See historical performance and comparison